Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Anne van Brussel"'
Autor:
Anja van de Stolpe, Cornelis J.H. van de Velde, Judith R. Kroep, Wim Verhaegh, J. Michael Dixon, Arran K. Turnbull, Andrew H. Sims, John W.M. Martens, Bart van der Burg, Susan Kloet, Elma Meershoek-Klein Kranenbarg, Sevgi E. Fruytier, Anne van Brussel, Eveline C. den Biezen-Timmermans, Ayoub Charehbili, Peter J.K. Kuppen, Erik J. Blok, Márcia A. Inda
Supplemental methods on estradiol measurements and sample analysis. Supplemental tables: 1. Public datasets used; 2. Estrogen concentrations on breast tissue; 3. Association of baseline parameters and ERPAS (Edinburgh cohort); 4. Logistic regression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50dd21e77f29c9ec8399f858f46f98f9
https://doi.org/10.1158/1535-7163.22510236.v1
https://doi.org/10.1158/1535-7163.22510236.v1
Autor:
Anja van de Stolpe, Cornelis J.H. van de Velde, Judith R. Kroep, Wim Verhaegh, J. Michael Dixon, Arran K. Turnbull, Andrew H. Sims, John W.M. Martens, Bart van der Burg, Susan Kloet, Elma Meershoek-Klein Kranenbarg, Sevgi E. Fruytier, Anne van Brussel, Eveline C. den Biezen-Timmermans, Ayoub Charehbili, Peter J.K. Kuppen, Erik J. Blok, Márcia A. Inda
Endocrine therapy is important for management of patients with estrogen receptor (ER)–positive breast cancer; however, positive ER staining does not reliably predict therapy response. We assessed the potential to improve prediction of response to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48b4f06713dad953982cc15f8a6c41e3
https://doi.org/10.1158/1535-7163.c.6539547.v1
https://doi.org/10.1158/1535-7163.c.6539547.v1
Autor:
Márcia Alves De Inda, Paul J. van Diest, Jan Willem Bikker, Cathy B. Moelans, Wim Verhaegh, Anja van de Stolpe, Paul van Swinderen, Eveline den Biezen, Anne van Brussel, Hans Van Zon
Publikováno v:
Cancers
Volume 13
Issue 6
Cancers, Vol 13, Iss 1345, p 1345 (2021)
Volume 13
Issue 6
Cancers, Vol 13, Iss 1345, p 1345 (2021)
Simple Summary Personalized breast cancer treatment with targeted therapy (e.g., tamoxifen or PI3K inhibitors) requires identification of responder patients. Phenotypical heterogeneity within the primary, and between primary tumor and metastases, may
Autor:
Márcia Alves De Inda, Sevgi E. Fruytier, Elma Meershoek – Klein Kranenbarg, Anne van Brussel, Wim Verhaegh, Susan L. Kloet, Bart van der Burg, Judith R. Kroep, J Michael Dixon, Eveline den Biezen-Timmermans, Andrew H. Sims, Anja van de Stolpe, Peter J. K. Kuppen, Arran K Turnbull, Cornelis J.H. van de Velde, A. Charehbili, E.J. Blok, John W.M. Martens
Publikováno v:
Molecular Cancer Therapeutics, 19(2), 680-689. AMER ASSOC CANCER RESEARCH
Inda, M A, Blok, E, Kuppen, P J K, Charehbili, A, den Biezen, E, van Brussel, A, Fruytier, S E, Kranenburg, M-K E, Kloet, S, Martens, J, Sims, A, Turnbull, A, Dixon, M, Verhaegh, W, Kroep, J R, van de Velde, C & Stolpe, A V D 2019, ' Estrogen Receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer ', Molecular Cancer Therapeutics . https://doi.org/10.1158/1535-7163.MCT-19-0318
Molecular Cancer Therapeutics, 19(2), 680-689. American Association for Cancer Research Inc.
Inda, M A, Blok, E, Kuppen, P J K, Charehbili, A, den Biezen, E, van Brussel, A, Fruytier, S E, Kranenburg, M-K E, Kloet, S, Martens, J, Sims, A, Turnbull, A, Dixon, M, Verhaegh, W, Kroep, J R, van de Velde, C & Stolpe, A V D 2019, ' Estrogen Receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer ', Molecular Cancer Therapeutics . https://doi.org/10.1158/1535-7163.MCT-19-0318
Molecular Cancer Therapeutics, 19(2), 680-689. American Association for Cancer Research Inc.
Endocrine therapy is important for management of patients with estrogen receptor (ER)–positive breast cancer; however, positive ER staining does not reliably predict therapy response. We assessed the potential to improve prediction of response to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::430b0cde2a833044fff0e0f2bcf9d0e3
https://hdl.handle.net/1887/3182284
https://hdl.handle.net/1887/3182284
Autor:
Anne van Brussel, Márcia Alves De Inda, Willem Jan van Weelden, Lisanne M M Schriever, Johanna M.A. Pijnenborg, Johan Bulten, Anja van de Stolpe, Leon F.A.G. Massuger, Marc P.L.M. Snijders, Louis J.M. van der Putten
Publikováno v:
British Journal of Cancer, 123, 785-792
British Journal of Cancer
British Journal of Cancer, 123, 5, pp. 785-792
British Journal of Cancer
British Journal of Cancer, 123, 5, pp. 785-792
Background Oestrogen receptor (ER) expression is a prognostic biomarker in endometrial cancer (EC). However, expression does not provide information about the functional activity of the ER pathway. We evaluated a model to quantify ER pathway activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beaa8763806bd98ed9fca05f44e18b0e
http://hdl.handle.net/2066/225484
http://hdl.handle.net/2066/225484
Autor:
Wim Verhaegh, Martijn Akse, Laurent Holtzer, Anne van Brussel, Eveline den Biezen-Timmermans, Yvonne Wesseling-Rozendaal, Márcia Alves De Inda, Henk van Ooijen, Sandra M. van den Bosch, Anke Pierik, Hans Van Zon
Publikováno v:
Cancer Research. 80:4261-4261
Introduction: Currently, the selection of targeted therapy is commonly based on genetic data, such as well-known gene mutations, but these mutations do not provide conclusive evidence for the functional activation of the affected pathway. For this re
Autor:
Christiane de Witz, Janneke Wrobel, Sebastian Huss, Anne van Brussel, Birthe Heitkötter, Ralf Hoffmann, Pieter C. Vos, Chris H. Bangma, Pierre Tennstedt, Thorsten Schlomm, Eveline den Biezen-Timmermans, Dianne Arnoldina Margaretha Wilhelmina Van Strijp, Martin Bögemann, Miles D. Houslay, Axel Semjonow, George S. Baillie
Publikováno v:
Van Strijp, D, De Witz, C, Vos, P C, Den Biezen-Timmermans, E, Van Brussel, A, Wrobel, J, Baillie, G S, Tennstedt, P, Schlomm, T, Heitkötter, B, Huss, S, Bögemann, M, Houslay, M D, Bangma, C, Semjonow, A & Hoffmann, R 2018, ' The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes ', Prostate Cancer, vol. 2018, 5821616 . https://doi.org/10.1155/2018/5821616
Prostate Cancer. Hindawi Limited
Prostate Cancer
Prostate Cancer. Hindawi Limited
Prostate Cancer
Purpose.To further validate the prognostic power of the biomarker PDE4D7, we investigated the correlation of PDE4D7 scores adjusted for presurgical clinical variables with longitudinal postsurgical biological outcomes.Methods.RNA was extracted from b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d471609761f3e3dda2de35fe8118f89b
https://kclpure.kcl.ac.uk/en/publications/2a75149f-0583-487b-8242-0cb89dd0951b
https://kclpure.kcl.ac.uk/en/publications/2a75149f-0583-487b-8242-0cb89dd0951b
Autor:
Márcia Alves De Inda, Pieter C. Vos, George S. Baillie, Hans Van Zon, Janneke Wrobel, Miles D. Houslay, Ralf Hoffmann, Anne van Brussel, Eveline den Biezen-Timmermans, Thorsten Schlomm, Pierre Tennstedt, Chris H. Bangma, Dianne Arnoldina Margaretha Wilhelmina Van Strijp
Publikováno v:
Alves de Inda, M, van Strijp, D, den Biezen-Timmermans, E, van Brussel, A, Wrobel, J, van Zon, H, Vos, P, Baillie, G S, Tennstedt, P, Schlomm, T, Houslay, M D, Bangma, C & Hoffmann, R 2018, ' Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes ', European Urology Focus, vol. 4, no. 3, pp. 376-384 . https://doi.org/10.1016/j.euf.2017.05.010
European Urology Focus, 4(3), 376-384. Elsevier
European Urology Focus, 4(3), 376-384. Elsevier
Background: The clinical metrics used to date to assess the progression risk of newly diagnosed prostate cancer patients only partly represent the true biological aggressiveness of the underlying disease. Objective: Validation of the prognostic bioma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1c3bdc9299950b8d74d92c9a068a46f
https://kclpure.kcl.ac.uk/ws/files/120353312/Validation_of_Cyclic_Adenosine_ALVES_DE_INDA_Accepted23May2019Publishedonline13June2017_GOLD_VoR_CC_BY_NC_ND_.pdf
https://kclpure.kcl.ac.uk/ws/files/120353312/Validation_of_Cyclic_Adenosine_ALVES_DE_INDA_Accepted23May2019Publishedonline13June2017_GOLD_VoR_CC_BY_NC_ND_.pdf
Autor:
Wim Verhaegh, Márcia Alves De Inda, CB Moelans, Jan Willem Bikker, Eveline den Biezen-Timmermans, Julie Gil, Anja van de Stolpe, Paul J. van Diest, Anne van Brussel
Publikováno v:
Journal of Clinical Oncology. 37:589-589
589 Background: Treatment with targeted drugs aims to block tumor driving signaling pathway(s). Drug choice is often based on a single preoperative primary breast cancer biopsy. It is important that biopsied cancer tissue is representative for the pr
Autor:
Louis J.M. van der Putten, Anne van Brussel, Henk van Ooijen, Márcia Alves De Inda, Leon F.A.G. Massuger, Anja van de Stolpe, Johanna M.A. Pijnenborg, Willem Jan van Weelden
Publikováno v:
Cancer Research. 78:2656-2656
Background Immunohistochemical (IHC) loss of expression of the estrogen (ER) and progesterone receptor (PR) from endometrial carcinomas is associated with high tumor grade, and with recurrent disease. However, expression of these receptors is not alw